Extended DAPT Results Need Verification After Multivessel PCI

Why the new result cannot yet guide reassessment

The supplied PubMed record identifies the Extended Dual Antiplatelet Therapy in Multivessel CAD trial and gives a publication date of July 16, 2026. It does not, within the material available for this brief, provide the trial’s sample size, endpoint definitions, event counts, effect estimates, confidence intervals, follow-up completeness, or safety results.

Those details are essential. A statement that extended dual antiplatelet therapy produced an “ischemic benefit” is not enough to determine its clinical importance. Clinicians need to know which events drove the result, whether the endpoint included softer outcomes such as repeat revascularization, and the absolute difference between treatment groups. The same applies to “major bleeding,” whose meaning depends on the bleeding definition, event count and statistical precision.

Reporting an unverified relative effect without the absolute rates could substantially distort the decision. A large relative reduction may correspond to a small absolute benefit when event rates are low. Conversely, a nonsignificant major-bleeding comparison does not establish equal safety if bleeding events were uncommon or the confidence interval remained compatible with clinically important harm.

What an adequate reading of DAPT-MVD requires

The central clinical question is well defined: among patients with multivessel coronary artery disease who completed 12 months after drug-eluting stent implantation without a major intervening event, does continuing clopidogrel with aspirin for another year improve net outcomes compared with stopping clopidogrel and continuing aspirin alone?

A reliable answer requires the randomized population and treatment contrast to be described precisely. Important details include whether the index PCI followed acute coronary syndrome or treatment of chronic coronary disease; how multivessel disease and successful PCI were defined; whether all intended lesions were treated; and which patients were excluded because of prior bleeding, anticoagulation, anemia, thrombocytopenia, kidney disease, or other high-risk features.

The analysis also needs to establish when randomization occurred. Trials that randomize only patients who remain event-free and adherent through the first post-PCI year study a selected population. Their results do not automatically apply at the time of the original PCI, to patients who stopped treatment earlier, or to those who experienced recurrent ischemia or clinically relevant bleeding during the initial 12 months.

The endpoint structure matters just as much. Myocardial infarction, definite or probable stent thrombosis, ischemic stroke and cardiovascular death generally carry different clinical weight from ischemia-driven revascularization. A composite can be statistically persuasive while being driven mainly by its more frequent, less severe component. Each component should therefore be examined alongside the primary result.

For bleeding, the report should identify the classification system and severity threshold. It should also present intracranial bleeding, fatal bleeding and treatment discontinuation when available. A p-value above 0.05 cannot by itself show that extended therapy caused no additional major bleeding; that conclusion depends on the observed difference and confidence interval.

How this fits with established evidence

The earlier DAPT Study showed why both sides of the tradeoff must remain visible. Among patients who had completed 12 months of dual antiplatelet therapy after coronary stenting, continuing a thienopyridine for another 18 months reduced stent thrombosis and major adverse cardiovascular and cerebrovascular events compared with placebo. Moderate or severe bleeding was more frequent with continued treatment.

That trial established that longer therapy can prevent ischemic events while increasing bleeding, but it did not make prolonged treatment the default for every post-PCI patient. Subsequent US guidance has emphasized balancing ischemic and bleeding risks, considering the clinical presentation, procedural characteristics, tolerance of treatment and need for oral anticoagulation.

Multivessel coronary disease may identify patients with a larger burden of atherosclerosis and greater potential for events arising beyond the treated stents. Yet anatomy alone does not determine net benefit. Age, prior myocardial infarction, diabetes, smoking, kidney function and procedural complexity may increase ischemic risk, while previous bleeding, anemia, frailty, low body weight, kidney dysfunction and concomitant anticoagulant or anti-inflammatory therapy can increase bleeding risk.

DAPT-MVD could refine this assessment if it enrolled a clearly characterized multivessel population and demonstrated a clinically meaningful absolute benefit without an unacceptable bleeding penalty. Until the numerical report is available and verified, however, the trial cannot support a change in practice or policy based only on its stated direction of effect.

What the evidence supports at 12 months

The post-PCI anniversary is a reassessment point, not an automatic stop or continuation date. Evidence and US guidance support reviewing the indication for the original PCI, interval ischemic events, bleeding history, medication tolerance, adherence, coronary complexity and competing need for anticoagulation.

For a stable, event-free patient, the relevant comparison is the expected absolute reduction in myocardial infarction or stent thrombosis against the expected absolute increase in clinically important bleeding. That calculation cannot be completed from DAPT-MVD without arm-by-arm event rates and uncertainty estimates.

The trial’s applicability may also be limited if it was conducted in a population with different bleeding susceptibility, body size, procedural practice or clopidogrel response from typical US cohorts. Geographic setting does not invalidate a result, but it can affect baseline risk and therefore absolute benefit. Funding, investigator conflicts, open-label treatment and blinded endpoint adjudication also need review before firm conclusions are drawn.

Important uncertainties

The most immediate limitation is evidence availability: the citation supplied for this assignment does not include enough retrievable trial information to report the design and outcomes to publication standard. Inventing or estimating the missing sample size, event rates, hazard ratios, confidence intervals or p-values would be unsafe.

Even after the full report is available, several questions will remain. A 12-month extension cannot establish the best duration beyond two years after PCI. An event-free randomized cohort may underrepresent patients at greatest bleeding risk. The study may also have limited power for individual outcomes such as cardiovascular death, stent thrombosis or intracranial hemorrhage.

Accordingly, interpret the evidence through absolute as well as relative effects, with separate attention to ischemic and bleeding endpoints. A neutral major-bleeding test should not be described as proof of no harm unless the confidence interval excludes a clinically significant increase.

Questions clinicians ask

Does multivessel PCI by itself justify another year of clopidogrel?

No. Multivessel disease may increase ischemic risk, but the net value of extended therapy also depends on prior myocardial infarction, procedural complexity, interval events and bleeding susceptibility. DAPT-MVD may inform that balance once its absolute event rates, endpoint definitions and confidence intervals can be checked.

Does a nonsignificant major-bleeding result mean extended DAPT is safe?

Not necessarily. Statistical nonsignificance may reflect few bleeding events or inadequate power rather than equivalent safety. Interpretation requires the arm-specific bleeding rates, effect estimate, confidence interval, bleeding definition and counts of fatal or intracranial events.

Which patients would the trial results apply to most directly?

The closest match would be patients meeting the trial’s enrollment criteria who remained event-free and tolerated aspirin plus clopidogrel through 12 months after drug-eluting stent PCI. The findings should not automatically be extrapolated to patients taking oral anticoagulants or those with earlier ischemic or bleeding events.

Should practice change before the complete report is reviewed?

The citation alone does not support a policy or treatment change. A defensible reassessment requires verified efficacy and safety results, including absolute differences, uncertainty estimates, follow-up duration, adherence, endpoint adjudication and the characteristics of the randomized population.

References

1. Extended Dual Antiplatelet Therapy in Multivessel CAD (DAPT-MVD Trial) — PubMed, 2026 2. Twelve or 30 Months of Dual Antiplatelet Therapy After Drug-Eluting Stents — The New England Journal of Medicine, 2014 3. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease — Circulation, 2016 4. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization — Circulation, 2022